[Federal Register Volume 74, Number 237 (Friday, December 11, 2009)]
[Notices]
[Page 65789]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-29527]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on September 28, 2009, Cedarburg 
Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, 
made application by renewal to the Drug Enforcement Administration 
(DEA) as a bulk manufacturer of the basic classes of controlled 
substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)...............  I
Dihydromorphine (9145).....................  I
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    In reference to drug code 7370 the company plans to bulk 
manufacture a synthetic Tetrahydrocannabinol. No other activity for 
this drug code is authorized for this registration.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than February 9, 2010.

    Dated: December 1, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-29527 Filed 12-10-09; 8:45 am]
BILLING CODE 4410-09-P